Printer Friendly

NEORX SIGNS COLLABORATION AND RESEARCH AGREEMENT WITH ORGANON INTERNATIONAL ON COLON CANCER THERAPY

 NEORX SIGNS COLLABORATION AND RESEARCH AGREEMENT WITH
 ORGANON INTERNATIONAL ON COLON CANCER THERAPY
 SEATTLE, Sept. 18 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today reported it has initiated a clinical trial of a colon cancer therapy product in collaboration with Organon International B.V., a subsidiary of AKZO. The clinical trial will assess the combined use of NeoRx's proprietary rhenium radiotherapy technologies and the completely human monoclonal antibodies for the treatment of colon cancer that have been generated by BRI, Rockville, Md., a laboratory of AKZO subsidiary Organon Teknika, that are currently under development as cancer therapeutics by Organon International.
 "The Organon agreement is a significant step in NeoRx's strategy to establish collaborative relationships funded by major pharmaceutical companies to develop effective antibody-based cancer therapeutics for each of the three major malignancies: breast cancer, colon cancer and lung cancer," said Paul G. Abrams, NeoRx's president and chief executive officer.
 Organon will fund the clinical trial activities, and will make milestone and license payments to NeoRx potentially worth more than $5 million. The agreement also provides for royalties to be paid to NeoRx on sales of the rhenium therapy products. There are over 160,000 new cases of colon cancer per year in the United States alone.
 The goal of the NeoRx-conducted phase I clinical trial is to determine the safety and therapeutic potential of the rhenium labeled human antibodies. "The availability of Organon's human antibodies may make it possible to administer multiple courses of treatment which previously were limited to single doses because of the development of HAMA (human anti-mouse antibody) responses," said Darrell Salk, M.D., NeoRx's vice president of medical and regulatory affairs. "Because they are of completely human origin, Organon's antibodies have considerable clinical potential and they have been shown to target human colon cancers very well in patient studies. NeoRx's rhenium labeled antibodies have also produced responses in colon cancer, but their administration was limited to single doses. Our labeling technologies permit the controlled and stable labeling of proteins with high doses of radioactivity."
 NeoRx has collaborative research agreements with Genentech, Inc. (NYSE: GNE) and Bristol-Myers Squibb Company (NYSE: BMY) employing the same rhenium radiotherapy technology using antibodies targeted primarily at breast and lung cancers.
 AKZO is one of the world's leading companies in selected areas of chemicals, fibers, proteins, salt and health care products. The company has some 63,000 employees, active at 350 locations in 50 countries around the world. Organon is one of the six business units that forms AKZO's Pharma Division. Organon currently employs approximately 6,900 people. Organon's product focus areas include contraception and gynecology, central nervous system, cardiovasculars and immunology & oncology.
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses, with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac(R) cancer imaging products and has completed a phase III trial for a third imaging product. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 9/18/92
 /CONTACT: Robert M. Littauer, vice president, chief financial officer and treasurer of NeoRx, 206-286-2519; or Anthony J. Russo, Ph.D., or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX) CO: NeoRx Corporation; Organon International B.V. ST: Washington, Maryland IN: MTC SU:


GK-OS -- NY010 -- 0995 09/18/92 09:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 18, 1992
Words:564
Previous Article:MARVIN M. EPSTEIN NAMED V.P. PUBLIC RELATIONS AND ADVERTISING OF THE AUSTIN COMPANY
Next Article:HOUGHTON MIFFLIN COMPANY ANNOUNCES PURCHASE OF ASSESSMENT DIVISION OF DLM, INC.
Topics:


Related Articles
NEORX TO GRANT LICENSE FOR RHENIUM CANCER THERAPY TO STERLING WINTHROP AS PART OF A $10 MILLION AGREEMENT
NEORX CORPORATION AND STERLING WINTHROP INC. SIGN LICENSE AGREEMENT FOR CANCER RADIOIMMUNOTHERAPY TECHNOLOGY
NEORX AND BOEHRINGER INGELHEIM COMPLETE STRATEGIC ALLIANCE
NEORX REPORTS 1992 FOURTH QUARTER RESULTS
NEORX DEMONSTRATES EFFICACY IN ANIMALS OF TWO THERAPEUTIC PRODUCT LINES
BIOSYS ANNOUNCES AGREEMENT WITH NEORX TO PRODUCE THERAPEUTIC PROTEINS
NEORX ANNOUNCES AGREEMENT WITH BIOSYS TO PRODUCE THERAPEUTIC PROTEINS
PHARMACOPEIA AND AKZO NOBEL/NV ORGANON ANNOUNCE RESEARCH COLLABORATION
OXFORD MOLECULAR GROUP SIGNS SECOND PROTEIN DESIGN COLLABORATION WITH NEORX CORP.
NeoRx Announces Start of Phase II Avicidin(R) Trials

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters